title: Acquired lipoprotein lipase deficiency associated with chronic urticaria. A new etiology for type I hyperlipoproteinemia.
abstract: Type I hyperlipoproteinemia (type I HLP) is a rare disorder of lipid metabolism characterized by fasting chylomicronemia and reduced postheparin plasma lipoprotein lipase (LPL) activity. Most cases of type I HLP are due to genetic defects in the LPL gene or in its activator, the apolipoprotein CII gene. Several cases of acquired type I HLP have also been described in the course of autoimmune diseases due to the presence of circulating inhibitors of LPL. Here we report a case of type I HLP due to a transient defect of LPL activity during puberty associated with chronic idiopathic urticaria (CIU). The absence of any circulating LPL inhibitor in plasma during the disease was demonstrated. The LPL genotype showed that the patient was heterozygous for the D9N variant. This mutation, previously described, can explain only minor defects in the LPL activity. The presence of HLP just after the onset of CIU, and the elevation of the LPL activity with remission of the HLP when the patient recovered from CIU, indicate that type I HLP was caused by CIU. In summary, we report a new etiology for type I HLP - a transient decrease in LPL activity associated with CIU and with absence of circulating inhibitors. This is the first description of this association, which suggests a new mechanism for type I HLP.
authors.affiliation: Departments of Biochemistry, Molecular Biology and Medicine, University of Zaragoza, Hospital Miguel Servet, Av. Isabel La Católica 1-3, 50009, Zaragoza, Spain.
authors.forename: A L
authors.initials: AL
authors.lastname: García-Otín
authors.forename: F
authors.initials: F
authors.lastname: Civeira
authors.forename: J
authors.initials: J
authors.lastname: Peinado-Onsurbe
authors.forename: C
authors.initials: C
authors.lastname: Gonzalvo
authors.forename: M
authors.initials: M
authors.lastname: Llobera
authors.forename: M
authors.initials: M
authors.lastname: Pocoví
mesh_terms: D000293:Adolescent; D016632:Apolipoprotein A-I / Q000097:blood; D001055:Apolipoproteins B / Q000097:blood; D001057:Apolipoproteins E / Q000235:genetics; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D002914:Chylomicrons / Q000097:blood; D005260:Female; D005838:Genotype; D006634:Histamine H1 Antagonists / Q000627:therapeutic use; D006801:Humans; D008072:Hyperlipoproteinemia Type I / Q000097:blood / Q000188:drug therapy / Q000209:etiology*; D008049:Lipase / Q000097:blood; D008071:Lipoprotein Lipase / Q000097:blood / Q000235:genetics; D014280:Triglycerides / Q000097:blood; D014581:Urticaria / Q000097:blood / Q000150:complications* / Q000188:drug therapy
chemical_list: D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D001057:Apolipoproteins E; D008076:Cholesterol, HDL; D002914:Chylomicrons; D006634:Histamine H1 Antagonists; D014280:Triglycerides; D002784:Cholesterol; D008049:Lipase; D008071:Lipoprotein Lipase